前收市價 | 0.0500 |
開市 | 0.0640 |
買盤 | 0.0000 x 3000 |
賣出價 | 0.0000 x 900 |
今日波幅 | 0.0500 - 0.0643 |
52 週波幅 | 0.0500 - 0.0643 |
成交量 | |
平均成交量 | 無 |
市值 | 無 |
Beta 值 (5 年,每月) | 無 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | 無 |
業績公佈日 | 無 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 無 |
Biotech may be a great sector for risk-seeking investors to find opportunity. That said, for every biotech stock worth buying, there are plenty that fit into the “biotech stocks to sell” category. For one, while biotechs are some of the riskier stocks out there, that doesn’t mean all of them offer the possibility of outsized rewards. Plenty of names in this category have massive downside risk, while at the same time offering questionable upside potential. Other biotechs may have tremendous upsid
In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D. But debt-fueled spending is becoming expensive. And selling stock will just dilute current shareholders. All companies will find it hard to deal with this, but none more so than companies with negative earnings and little cash on hand. While some companies can delay the inevitable for a surprisingly long time, gravity is likely to catch up to unprofitable companies eventu